United Therapeutics Corp UTHR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
-
United Therapeutics Corporation Acquires Thymmune Therapeutics
-
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
-
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
-
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
-
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
-
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
-
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
Trading Information
- Previous Close Price
- $535.83
- Day Range
- $522.64–539.71
- 52-Week Range
- $272.16–607.84
- Bid/Ask
- $526.71 / $528.51
- Shares Outstanding
- 42.45M
- Market Cap
- $26.27B
- Volume/Avg
- 236,309 / 474,604
Key Statistics
- Price/Earnings (Normalized)
- 17.90
- Price/Sales
- 8.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 11.06%
Company Profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,400
- Website
- https://www.unither.com
Valuation
|
Metric
|
UTHR
|
|---|---|
Price/Earnings (Normalized) | 17.90 |
Price/Book Value | 3.83 |
Price/Sales | 8.04 |
Price/Cash Flow | 14.68 |
Price/Earnings
UTHR
Financial Strength
|
Metric
|
UTHR
|
|---|---|
Quick Ratio | 4.12 |
Current Ratio | 4.79 |
Interest Coverage | 87.95 |
Quick Ratio
UTHR
Profitability
|
Metric
|
UTHR
|
|---|---|
Return on Assets (Normalized) | 18.96% |
Return on Equity (Normalized) | 21.24% |
Return on Invested Capital (Normalized) | 19.14% |
Return on Assets
UTHR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|d@p@BYMN | LOCK|kMX^ | $67B | |||
| Haleon PLC ADR
HLN
| LOCK|XZljp! | LOCK|Vy | $44B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|d&^Wc%Wt | LOCK|k?N? | $37B | |||
| Zoetis Inc Class A
ZTS
| LOCK|%bDs%GS% | LOCK|y@ | $32B | |||
| Viatris Inc
VTRS
| LOCK|V%h?@%m | LOCK|htR | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|zH | LOCK|?c^ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|f>^<dh$ | LOCK|>j | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|%?@d@x | LOCK|wV | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|d?%<X!G | LOCK|^>>Y | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|&%>ZLMZ | LOCK|F?% | $1B |
United States